The future of platelet monitoring

December 18, 2012
Recorded: November 6, 2012

The ARCTIC trial found no benefit of platelet-function testing and modification of treatment in patients receiving drug-eluting stents, adding yet another setback to this approach.

Dr Robert Harrington sits down with Drs Gilles Montalescot and Lars Wallentin to talk about what these results mean and what's next for platelet-function monitoring.

Chair

Robert Harrington MD
Arthur L Bloomfield Professor of Medicine and Chair, Department of Medicine
Stanford University
Stanford, CA

Dr Harrington has served as an advisor or consultant for APT Therapeutics, AstraZeneca, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Cortex, CSL Behring, Daiichi Sankyo, Eisai, Genentech, Gilead, Johnson & Johnson, Merck, Mitsubishi Tanabe, Momenta, Nidus Center for Scientific Enterprise, Orexigen, Pfizer, Regado, Sanofi, and the Medicines Company. He has received grants for clinical research from AstraZeneca, Baxter, Bristol-Myers Squibb, CSL Behring, GlaxoSmithKline, Merck, Portola, Sanofi, and the Medicines Company.
Panelists

Gilles Montalescot MD PhD
Professor of Cardiology
Institut de Cardiologie
Hôpital la Pitié-Salpêtrière
Paris, France

Dr Montalescot has received grants for clinical research from Medica, AstraZeneca, Biotronik, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Medtronic, Nanosphere, Pfizer, Roche, Sanofi, Stago, Stentys, and Thermo Fisher. Dr Montalescot has consulted for or received lecture fees from Abbott, AstraZeneca, Atrium Medical, Bayer, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Indegene Lifesystems, Menarini Group, Merck Sharp and Dohme, Nanosphere, Novartis, Pfizer, Portola, Sanofi, the Medicines Company, Asante, Lead-up, and Springer.

Lars Wallentin MD PhD
Professor of Cardiology
Director, Uppsala Clinical Research Center
University Hospital
Uppsala, Sweden

Dr Wallentin has served as an advisor or consultant for Athera Biotechnologies, CSL Behring, Evolva, Portola, and Regado Biosciences. He has received grants for clinical research from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Schering-Plough.

Related Links: